Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Alogliptin vs. Acarbose in Chinese Type 2 Diabetes Mellitus (T2DM) Patients With High CV Risk or CHD Treated With Aspirin and Inadequately Controlled With Metformin Monotherapy or Drug Naive

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria :~* Type 2 Diabetes Mellitus patients (age ≥18yr) drug naive or treated with metformin monotherapy (≥1500 mg/day or individually maximally tolerated dose) for at least 12 weeks with a Hemoglobin A1c between ≥ 7.5% and ≤ 11.0% at screening.~* Fasting plasma glucose ≤13.3mmol/L(≤240mg/dL) at screening.~* Patients with documented history of Coronary Heart Disease (CHD) or High cardiovascular(CV) risk.~* History of CHD, defined as previous myocardial infarction or unstable/stable angina.~* High CV risk, defined as male or female (age\> 50 yr), combined with at least one of these risk factors as below: family history of cardiovascular disease, history of hypertension, smoking, dyslipidemia, or protein urine.~* Already treated with Aspirin or should start Aspirin treatment at physician's discretion.~Exclusion criteria:~* Diagnosis of type 1 diabetes, diabetes resulting from pancreatic injury or secondary forms of diabetes.~* Previous treatment with any Dipeptidyl Peptidase -4 inhibitor or glucagon-like peptide-1 (GLP-1) receptor agonists within 1 year of screening;~* Any contraindication of Aspirin, Dipeptidyl Peptidase- 4 inhibitor and Alpha-glucosidase inhibitor.~* Clinically apparent liver disease or moderate /severe renal impairment or end-stage renal disease~* Unstable CV disorder including heart failure (New York Heart Association class III or IV), refractory angina, uncontrolled arrhythmias, and severe uncontrolled hypertension (systolic blood pressure ≥180 mmHg, or diastolic blood pressure ≥105 mmHg).~* Acute coronary syndrome event within 6 month before randomization~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alogliptin (Type: EXPERIMENTAL): Single dose of alogliptin once daily for 16 weeks
- Acarbose (Type: ACTIVE_COMPARATOR): Thrice daily dose of acarbose Dose 1 for 7 days then titrate to thrice daily dose of of acarbose Dose 2

Based on this trial design, predict the completion outcome and termination type (if applicable).